October 30, 2017 06:29 AM EDT

Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer

John Carroll

Editor & Founder

→ London-based Mereo BioPharma has picked off an option on the rights to a Phase II drug from AstraZeneca, which has been steadily divesting itself …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Small personalized vaccine trial sees progress in late-stage kidney cancer

Revance and Crown are almost ready to close their deal after earlier bidding war

Trump 2.0 blog: Musk's DOGE team searches CMS payment systems for fraud

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Mereo bags rights to the lat­est As­traZeneca castoff, shifts fo­cus; Neos re­jects buy­out of­fer

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer